noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Veradigm Inc.

A Single-Specialty Independent Practice Shares Highlights of Their[...]
P10 Inc.

P10, Inc. Announces HPS Investment Partners and Enhanced Capital Launch[...]
Heartland Express Inc.

Heartland Express, Inc. Announces Participation in Upcoming Conference

Company News

Mitesco Inc.

11/25/2024 | Press release | Distributed by Public on 11/25/2024 16:05

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

mitesco20240930_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended September 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-53601

MITESCO, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada	87-0496850
(State Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

505 Beachland Blvd., Suite 1377

Vero Beach, Florida 32963

(Address of principal executive offices) (Zip code)

844-383-8689

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large, accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large, accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

As of November 25, 2024, the registrant had 9,384,414 shares of common stock issued and outstanding.

Table of Contents

	Page
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	4
	Consolidated Balance Sheets as of September 30, 2024, and December 31, 2023	4
	Consolidated Statements of Operations for the three and nine months ended September 30, 2024, and 2023	5
	Consolidated Stockholder's Deficit for the three and nine months ended September 30, 2024, and 2023	6
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2024, and 2023	7
	Notes to Consolidated Financial Statements	8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations.	32

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	36

Item 4.	Controls and Procedures.	36

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.	37

Item 1A.	Risk Factors.	38

Item 2.	Sale of Unregistered Securities.	39

Item 3.	Defaults Upon Senior Secured Securities.	39

Item 4.	Mine Safety Disclosures.	39

Item 5.	Other Information.	39

Item 6.	Exhibits.	39

Signatures	41

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MITESCO, INC.

CONSOLIDATED BALANCE SHEETS

	September 30, 2024 (Unaudited)			December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	31,822			$	2,838
Prepaids and other current assets		29,500				-
Total current assets		61,322				2,838

Total assets	$	61,322			$	2,838

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued liabilities	$	5,370,599			$	7,838,112
Accrued interest		378,453				348,821
Accrued interest - related party		50,481				61,792
Derivative liabilities		152,945				152,945
Lease liability - operating lease, current		99,477				99,477
Notes payable, net		1,023,019				945,429
Notes payable - related parties, net		166,912				300,012
SBA loan payable		401,547				421,788
Other current liabilities		96,136				121,136
Preferred stock dividends payable		1,690,501				1,551,833
Preferred stock dividends payable - related parties		177,776				73,364
Legal settlements		2,452,768				2,219,886
Total current liabilities		12,060,614				14,134,595

Total liabilities		12,060,614				14,134,595

Stockholders' deficit
Preferred stock, $0.01 par value, 100,000,000 shares authorized; 500,000 shares designated Series A; 3,000,000 shares designated Series C; 10,000,000 shares designated Series D; 10,000 shares designated as Series E; 140,000 shares designated as Series F, and 27,324 shares designated Series X.
Preferred stock, Series A, $0.01 par value, 0 shares issued and outstanding as of September 30, 2024, and December 31, 2023		-				-
Preferred stock, Series C, $0.01 par value, 0 shares issued and outstanding as of September 30, 2024, and December 31, 2023		-				-
Preferred stock, Series D, $0.01 par value, 150,000 and 250,000 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively		1,500				2,500
Preferred stock, Series F, $0.01 par value, 14,665 and 20,057 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively		146				201
Preferred stock, Series X, $0.01 par value, 24,587 and 24,227 shares issued and outstanding at September 30, 2024, and December 31, 2023, respectively		246				242
Common stock, $0.01 par value, 500,000,000 shares authorized, 8,508,756 and 5,567,957 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		85,091				55,680
Additional paid-in capital		48,249,442				47,856,444
Accumulated deficit		(60,335,717	)			(62,046,824	)

Total stockholders' deficit		(11,999,292	)			(14,131,757	)

Total liabilities and stockholders' deficit	$	61,322			$	2,838

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended			Nine Months Ended
	September 30, 2024			September 30, 2023			September 30, 2024		September 30, 2023

Revenue	$	23,500			$	-		$	29,500		$	-

OPERATING EXPENSES:

Cost of operations		8,802				-			8,802			-
General and administrative		230,940				41,876			712,293			2,230,056
Impairment of fixed assets		-				-			-			132,000

Total operating expenses		239,742				41,876			721,095			2,362,056

Net loss from operations		(216,242	)			(41,876	)		(691,595	)		(2,362,056	)

OTHER INCOME (EXPENSES):
Interest expense		(50,979	)			(69,776	)		(159,206	)		(1,575,278	)
Interest expense - related parties		(10,587	)			(34,820	)		(26,133	)		(108,343	)
Equity investment incentive		-				(1,214,970	)		-			(7,644,077	)
Gain on termination of operating lease		636,485				-			869,690			-
Gain on settlement of notes payable		693,768				-			693,768			25,000
Gain on settlement of accounts payable		1,024,583				159,524			1,024,583			192,616
Loss on settlement of true-up obligations		-				-			-			(119,370	)
Loss on legal settlement		-				-			-			(18,759	)
Other income		-				40,622						60,719
(Loss) Gain on revaluation of derivative liabilities		-				(14,725	)		-			(85,765	)
Total other income (expense)		2,293,270				(1,134,145	)		2,402,702			(9,273,257	)

Net income (loss) from continuing operations		2,077,028				(1,176,021	)		1,711,107			(11,635,313	)
Net income (loss) from discontinued operations		-				(376,352	)		-			(3,075,155	)
Consolidated net loss		2,077,028				(1,552,373	)		1,711,107			(14,710,468	)

Preferred stock dividends		(18,637	)			(924,624	)		(878,092	)		(1,001,745	)
Preferred stock dividends - related parties		(4,888	)			(78,357	)		(140,888	)		(78,357	)

Net income (loss) available to common shareholders	$	2,053,503			$	(2,555,354	)		692,127			(15,790,570	)

Basic net income (loss) per common share - continuing operations	$	0.32			$	(0.41	)		0.12			(2.52	)
Basic net income (loss) per common share - discontinued operations	$	0.00			$	(0.07	)		0.00			(0.61	)
Basic net income (loss) per common share	$	0.32			$	(0.48	)		0.12			(3.13	)

Diluted net income (loss) per common share - continuing operations	$	0.29			$	(0.41	)		0.11			(2.52
Diluted net income (loss) per common share - discontinued operations	$	0.00			$	(0.07	)		0.00			(0.61
Diluted net income (loss) per common share	$	0.29			$	(0.48	)		0.11			(3.13

Basic weighted average shares outstanding		6,348,878				5,329,816			5,916,675			5,048,070
Diluted weighted average shares outstanding		6,984,629				5,329,816			6,552,426			5,048,070

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024, and 2023

(UNAUDITED)

	Preferred Stock Series C			Preferred Stock Series D			Preferred Stock Series F	Preferred Stock Series X		Common Stock			Additional Paid-in		Common Stock		Accumulated
	Shares			Amount			Shares	Amount		Shares			Amount		Shares		Amount		Shares			Amount			Capital	Subscribed	Deficit		Total

Balance, December 31, 2023		-			$	-		250,000		$	2,500			20,057		$	201			24,227			$	242		5,567,957	$	55,680		$	47,856,444		$	-		$	(62,046,824	)	$	(14,131,757	)

Shares issued for Series X dividends		-				-		-			-			-			-			-				-		66,070		661			52,195			-			-			52,856
Preferred stock dividends		-				-		-			-			-			-			-				-		-		-			(638,565	)		-			-			(638,565	)
Net income		-				-		-			-			-			-			-				-		-		-			-			-			46,524			46,524

Balance, March 31, 2024		-				-		250,000			2,500			20,057			201			24,227				242		5,634,027		56,341			47,270,074			-			(62,000,300	)		(14,670,942	)

Shares issued for Series X dividends		-				-		-			-			-			-			-				-		24,555		246			19,396			-			-			19,642
Shares issued as compensation		-				-		-			-			-			-			-				-		300,000		3,000			99,000			-			-			102,000
Preferred stock dividends		-				-		-			-			-			-			-				-		-		-			(356,890	)		-			-			(356,890	)
Series X shares issued as compensation		-				-		-			-			-			-			7,200				72		-		-			179,928			-			-			179,928
Net loss		-				-		-			-			-			-			-				-		-		-			-			-			(412,445	)		(412,445	)

Balance, June 30, 2024		-			$	-		250,000		$	2,500			20,057		$	201			31,427			$	314		5,958,582	$	59,587		$	47,211,508		$	-		$	(62,412,745	)	$	(15,138,635	)

Shares issued for conversion of account payable		-				-		-			-			-			-			-				-		231,886		2,319			58,535			-			-			60,854
Shares issued for conversion of notes payable and accrued interest		-				-		-			-			-			-			-				-		145,493		1,456			175,600			-			-			177,056
Shares issued for conversion of notes payable and accrued interest - related parties		-				-		-			-			-			-			-				-		45,092		451			37,827			-			-			38,278
Shares issued for conversion of Series F preferred shares and accrued dividends		-				-		-			-			(5,392	)		(55	)		-				-		1,515,065		15,151			650,489			-			-			655,585
Shares issued for conversion of Series D preferred shares and accrued dividends		-				-		(100,000	)		(1,000	)		-			-			-				-		30,802		308			18,867			-			-			18,175
Shares issued for conversion of Series X preferred shares		-				-		-			-			-			-			(6,840	)			(68	)	56,263		563			(495	)		-			-			-
Shares issued for Series X dividends		-				-		-			-			-			-			-				-		25,573		256			19,396			-			-			19,642
Shares issued as compensation		-				-		-			-			-			-			-				-		500,000		5,000			101,250			-			-			106,250
Preferred stock dividends		-				-		-			-			-			-			-				-		-		-			(23,525	)		-			-			(23,525	)
Net income		-				-		-			-			-			-			-				-		-		-			-			-			2,077,028			2,077,028

Balance, Sept 30, 2024		-			$	-		150,000		$	1,500			14,665		$	146			24,587			$	246		8,508,756	$	85,091		$	48,249,442		$	-		$	(60,335,717	)	$	(11,999,292	)


Balance, December 31, 2022		1,047,619				10,476		3,100,000			31,000			-			-			24,227				242		4,630,372		46,305			29,452,514			36,575			(48,714,461	)		(19,137,349	)

Shares issued for conversion of note payable		-				-		-			-			-			-			-				-		57,138		571			82,885			-			-			83,456
Vesting of stock options issued to employees		-				-		-			-			-			-			-				-		-		-			933			-			-			933
Shares issued to service providers		-				-		-			-			-			-			-				-		300,000		3,000			894,000			-			-			897,000
Shares issued for Series X dividends		-				-		-			-			-			-			-				-		8,063		81			35,248			-			-			35,329
Preferred stock dividends		-				-		-			-			-			-			-				-							(79,818	)		-			-			(79,818	)
Net loss		-				-		-			-			-			-			-				-		-		-			-			-			(5,613,825	)		(5,613,825	)

Balance, March 31, 2023		1,047,619				10,476		3,100,000			31,000			-			-			24,227				242		4,995,573		49,957			30,385,762			36,575			(54,328,286	)		(23,814,274	)

Shares issued as commission for fundraising		-				-		-			-			-			-			-				-		2,952		30			3,778			-			-			3,808
Shares issued for true-up agreement		-				-		-			-			-			-			-				-		94,738		947			118,423			-			-			119,370
Shares issued legal settlement		-				-		-			-			-			-			-				-		22,174		222			18,537			-			-			18,759
Shares issued for previously subscribed shares		-				-		-			-			-			-			-				-		2,926		30			36,545			(36,575	)		-			-
Shares issued for Series X dividends		-				-		-			-			-			-			-				-		20,212		202			25,033			-			-			25,235
Vesting of stock options issued to employees		-				-		-			-			-			-			-				-		-		-			933			-			-			933
Series F shares issued for conversion of accounts payable		-				-		-			-			147			2			-				-		-		-			146,212			-			-			146,214
Series F shares sold for cash		-				-		-			-			1,746			17			-				-		-		-			1,655,483			-			-			1,655,500
Series F shares issued for conversion of Series C and Series D preferred shares		(1,047,619	)			(10,476	)	(2,350,000	)		(23,500	)		6,344			63			-				-		-		-			2,809,415			-			-			2,775,502
Series F shares issued for conversion of debt		-				-		-			-			8,116			81			-				-		-		-			8,612,993			-			-			8,613,074
Series A dividends previously satisfied		-				-		-			-			-			-			-				-		-		-			10,967			-			-			10,967
Preferred stock dividends		-				-		-			-			-			-			-				-		-		-			(468,545	)		-			-			(457,578	)
Net loss		-				-		-			-			-			-			-				-		-		-			-			-			(7,544,270	)		(7,544,270	)

Balance, June 30, 2023		-			$	-		750,000		$	7,500			16,353		$	163			24,227			$	242		5,138,575	$	51,388		$	43,355,536		$	-		$	(61,872,556	)	$	(18,457,727	)

Conversion of accounts payable to common stock		-				-		-			-			-			-			-				-		224,338		2,244			76,275			-			-			18,759
Conversion of accrued salary, debt and board fees to common stock - related parties		-				-		-			-			-			-			-				-		181,606		1,816			3,632			(36,575	)		-			5,448
Conversion of debt to Series F preferred stock						--		-			-			911			-			-				-		-		-			910,093			-			-			910,102
Conversion of debt accrued salaries to Series F preferred stock - RP		-				-		-			-			2,138			22			-				-		-		-			2,137,032			-			-			2,137,054
Transaction costs Series F preferred stock sold for cash		-				-		-			-			-			-			-				-		-		-			(72,000	)		--						(72,000	)
Vesting of stock options issued to employees		-				-		-			-			-			-			-				-		-		-			933			-			-			933
Preferred stock dividends		-				-		-			-			-			-			-				-		-		-			(531,738	)		-			-			(531,738	)
Net loss		-				-		-			-			-			-			-				-		-		-			-			-			(1,552,373	)		(1,552,373	)

Balance, September 30, 2023		-			$	-		750,000		$	7,500			19,402		$	194			24,227			$	242		5,544,519	$	55,448		$	45,879,763		$	-		$	(63,424,829	)	$	(17,481,682	)

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30, 2024			September 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) from continuing operations	$	1,711,107			$	(11,635,313	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment of fixed assets		-				132,000
Depreciation expense		-				11,393
Penalties on notes payable		-				1,102,778
Equity investment incentive						7,644,077
Amortization of discount on notes payable		-				32,011
Amortization of discount on notes payable - related parties		-				19,587
Share based compensation		388,250				899,799
Shares issued as compensation for fundraising		-				3,808
Shares issued for true-up liability		-				119,370
Gain on settlement of note payable		(693,768	)			(25,000	)
Gain on settlement of accounts payable		(1,024,583	)			(192,616	)
Gain (loss) on lease terminations		(869,690	)			-
Gain (loss) on revaluation of derivative liabilities		-				85,765
Loss on legal settlement		-				18,759
Other income		-				(40,622	)
Changes in operating assets and liabilities:
Accounts receivable		(29,500	)			-
Prepaid expenses		-				51,632
Accounts payable and accrued liabilities		(304,504	)			850,561
Accrued interest		391,273				404,191
Accrued interest - related parties		31,640				101,918
Net cash used in operating activities from continuing operations		(399,775	)			(415,902	)
Net cash used in operating activities from discontinued operations		-				(430,045	)
Net cash used in operating activities		(399,775	)			(845,947	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Net cash provided by investing activities from discontinued operations		-				102,967
Net cash provided by investing activities		-				102,967

CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on SBA Loan		(20,241	)			(4,836	)
Proceeds from notes payable, net of discounts		449,000				-
Proceeds from sale of Series F Preferred stock, net of fees		-				738,500


Net cash provided by financing activities		428,759				733,664

Net change in cash		28,984				(9,316	)
Cash at beginning of period		2,838				35,623
Cash at end of period	$	31,822			$	26,307

Supplemental disclosure of cash flow information:
Cash paid for interest	$	-			$	-
Cash paid for taxes	$	-			$	-

Supplemental disclosure of financing cash flow information:
Stock Issued for common stock subscribed	$	-			$	36,575
Preferred stock dividends	$	1,018,980			$	1,080,102
Conversion of accounts payable to Series F preferred stock	$	-			$	146,214
Conversion of Series C and Series D preferred stock to Series F preferred stock	$	-			$	420,681
Conversion of notes payable and accrued interest to Series F preferred stock	$	-			$	11,158,379
Shares issued for Series X dividends	$	92,140			$	60,564
Conversion of accounts payable to common stock	$	45,000			$	78,519
Conversion of notes payable to common stock	$	177,056			$	83,456
Conversion of notes payable to common stock - related party	$	650,940			$	-
Conversion of Series F Preferred Stock and accrued dividends to common stock	$	665,640			$	-
Conversion of Series D Preferred Stock and accrued dividends to common stock	$	19,175			$	-
Conversion of Series X Preferred Stock and accrued dividends to common stock	$	193			$	-
Series A accrued dividends reclassified to APIC from prior transaction	$	-			$	10,967
Increase in capital expenditures included in accounts payable	$	-			$	110,511

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

MITESCO, INC.

UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Description of Business

Company Overview

Mitesco, Inc. (the "Company," "we," "us," or "our") was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a "spin out" of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company completed a move of its corporate status to Nevada from Delaware in order to effect reduced costs.

The details can be found at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518523001074/mitesco20231016_8k.htm.

From 2020 through 2022, our operations were focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability.

We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS).

In June 2024 we announced the formation of two (2) new wholly owned business units, Centcore, LLC, who is providing data center services including cloud computing and application hosting, and Vero Technology Ventures, LLC, whose aim is to seek investment and acquisition opportunities, generally in the areas of cloud computing and data center related applications.

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as "managed services offerings" or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. The second focus involves hosting application software developed by software vendors, from which they will sell the use of the software by their end user clients on a "cloud" basis. By taking this approach, we hope to gain the business of the vendor, and their clients, perhaps allowing us to grow at a faster rate with lower cost of sales. We have developed the "Centcore Partner Program" where we will help promote the software vendors who are hosting in our data centers. If we are successful helping the vendor grow his business, we will have provided a "value added service", and benefit from increased utilization of our computing resources by not only the vendor, but also his new end user clients. Our initial focus for this area is on software providers who serve the "infrastructure" market doing design, engineering, construction and maintenance of significant assets. We desire to create "life cycle" relationships with both the design teams, and owners which may include private owners such as manufacturers and utilities, or publicly owned assets for municipalities, states or federal governments, domestically and internationally.

Note 2: Going Concern

As of September 30, 2024, the Company had cash and cash equivalents of approximately $32,000, current liabilities of approximately $12.1 million, and has incurred significant losses from the previous clinic operations. As previously noted, we made a strategic decision to reduce our capital needs by closing our entire clinic operations in the fourth quarter of 2022 and releasing our entire staff, due to lack of profitability. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

Table of Contents

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company's continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company's ability to access capital, which could in the future negatively affect the Company's liquidity. In addition, a recession or market correction due to these factors could materially affect the Company's business and the value of its common stock.

Note 3: Summary of Significant Accounting Policies

Basis of Presentation - The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America ("GAAP").

The consolidated financial statements and related disclosures as of September 30, 2024, are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2023, and 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the full year ended December 31, 2024.

Principles of Consolidation - The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC, The Good Clinic, LLC, Vero Technology Ventures, LLC, and Centcore, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company's management, restrictions and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities' operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 810 - Consolidation ("ASC 810"), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises that are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation.

Table of Contents

The following table presents the effect of potential dilutive issuances for the three and nine months ended September 30, 2024, and 2023:

	Three Months Ended		Nine Months Ended
	September 30, 2024		September 30, 2023			September 30, 2024		September 30, 2023

Net profit (loss) attributable to common stockholders	$	2,053,503		$	(2,555,354	)	$	692,127	$	(15,790,570	)
Preferred stock dividends		3,883			-			27,362		-
Interest expense associated with convertible debt		-			-			-		-
Net income (loss) for dilutive calculation	$	2,057,386		$	(2,555,354	)	$	719,489	$	(15,790,570	)

Basic weighted average shares outstanding		6,348,878			5,329,816			5,916,675		5,048,070
Dilutive effect of preferred stock		7,394			-			7,394		-
Dilutive effect of convertible debt		-			-			-		-
Dilutive effect of common stock warrants		628,357			-			628,357		-
Weighted average shares outstanding for diluted net income (loss) per share		6,984,629			5,329,816			6,552,426		5,048,070

Discontinued Operations - The accompanying financial statements are prepared with the guidance of ASU 2014-08, "Reporting Discontinued Operations", and ASC Topic 205, Presentation of Financial Statements, and ASC Topic 360, Property, Plant and Equipment.

Recent Accounting Standards - In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Note 4: Discontinued Operations

In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. On December 8, 2023, the Company sold the remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, a company organized by Michael C. Howe, the former CEO of The Good Clinic, LLC for total consideration of approximately $2.5 million. ASC 360-10-45-9 requires that a long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which a set of criteria have been met, including criteria that the sale of the asset (disposal group) is probable and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. This criterion was achieved on December 8, 2023. Additionally, the discontinued operations are comprised of the entirety of The Good Clinic, LLC. For comparability purposes certain prior period line items relating to the assets held for sale have been reclassified and presented as discontinued operations for all periods presented in the accompanying consolidated statements of net loss and comprehensive loss and the consolidated balance sheets.

The Company had no assets or liabilities classified that were classified as held as part of discontinued operations as of September 30, 2024, or December 31, 2023.

Table of Contents

The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations:

	Three Months Ended		Nine Months Ended
	September 30,		September 30,			September 30,		September 30,
	2024		2023			2024		2023
Revenue	$	-		$	-		$	-	$	-
Cost of goods sold		-			-			-		-
Gross margin					-			-		-

Selling, general, and administrative expenses		-			(385,252	)		-		(991,177	)
Impairment of assets		-			-			-		(2,211,462	)

Other (income) expense:
Gain on termination of operating lease		-			-			-		287,897
Gain on sale of assets					8,876					8,876
Gain on settlement of accounts payable					81,263					81,263
Interest expense		-			(81,238	)		-		(250,551	)
Loss from discontinued operations, net of tax	$	-		$	(376,352	)	$	-	$	(3,075,155	)

The following information presents the major classes of line items constituting significant operating and investing cash flow activities in the consolidated statements of cash flow relating to discontinued operations:

	Nine Months Ended
	September 30,		September 30,
	2024		2023

Depreciation expense	$	-		$	81,764
Impairment of property and equipment	$	-		$	2,211,462
Changes in accounts payable and accrued liabilities	$	-		$	444,884

Note 5: Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following at September 30, 2024, and December 31, 2023:

	September 30,		December 31,
	2024		2023
Trade accounts payable	$	4,627,103		$	7,094,334
Accrued payroll and payroll taxes		743,496			743,778
Total accounts payable and accrued liabilities	$	5,370,599		$	7,838,112

Note 6: Right to Use Assets and Lease Liabilities - Operating Leases

The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. The Company's lease expense was entirely comprised of operating leases and is reported as a component of discontinued operations as a result of closing of the clinics and the subsequent sale of the assets. As of December 31, 2023, the Company had impaired all balances of the related right to use assets.

Table of Contents

Operating lease liabilities are summarized below:

	September 30, 2024			December 31, 2023
Lease liability	$	99,477			$	99,477
Less: current portion		(99,477	)			(99,477	)
Lease liability, non-current	$	-			$	-

As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023, or the nine months ending September 30, 2024. As of September 30, 2024, the Company has either settled amounts owed or entered into default judgements for all leases except for the office lease, which we believe is nominal. For all leases for which a legal settlement has been entered into, all amounts have been reclassified to legal settlements as of September 30, 2024, and December 31, 2023.

For the period ended December 31, 2024	$	99,477
For the period ended December 31, 2025		-
For the period ended December 31, 2026		-
For the period ended December 31, 2027		-
For the period ended December 31, 2028		-
Thereafter		-
Total	$	99,477
Less: Present value discount		-
Lease liability	$	99,477

As of December 31, 2023, the Company has entered into settlement agreements for certain of our leases in the amount of $2,219,886 which is recorded as Legal Settlements in the accompanying balance sheet. During the nine months ended September 30, 2024, the Company recorded a gain of $869,690 as a result of a final settlement in addition to reclassifying certain accounts payable related to the leases to legal settlements. As of September 30, 2024, the Company has total legal settlement agreements in the amount of $2,452,768 which is recorded as Legal Settlements in the accompanying balance sheet.

Note 7: SBA Loan Payable

PPP Loan Conversion to SBA Loan

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or "PPP", established as part of the Corona Virus Aid, Relief and Economic Security Act ("CARES Act") and administered by the U.S. Small Business Administration (the "SBA"). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the "PPP Loan"). The PPP Loan bears interest at the rate of 1% per year.

On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The SBA confirmed the balance due on the loan, including principal and interest, was $467,117. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the nine months ended September 30, 2024, the Company made principal payments of $20,241 on this loan and recorded interest in the amount of $3,116.

Table of Contents

Note 8: Notes Payable

The following table summarizes the outstanding notes payable as of September 30, 2024, and December 31, 2023, respectively:

	September 30, 2024		December 31, 2023
Kishon Note	$	431,666		$	431,666
Finnegan Note 1		51,765			51,765
Finnegan Note 2		32,353			32,353
Schrier Note		25,882			25,882
Nommsen Note		-			64,705
Caplan Note		-			64,705
Finnegan Note 3		32,353			32,353
Lightmas Note		-			66,000
Lewis Note		-			33,000
Goff Note		-			33,000
Hagan Note		-			110,000
Cavalry Note 1		25,000			-
Cavalry Note 2		50,000			-
Mercer Note 1		25,000			-
Mercer Note 2		50,000			-
ABJ Note		50,000			-
Cavalry Note 3		33,000			-
Mercer Note 3		33,000			-
ABJ Note 2		33,000			-
Cavalry Note 4		25,000			-
Mercer Note 4		25,000			-
ABJ Note 3		25,000			-
Mercer Note 4		25,000			-
ABJ Note 3		25,000			-
Total Notes Payable		998,019			945,429

Current Portion		998,019			945,429
Long-term portion	$	-		$	-

Kishon Note

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the "Kishon Agreement") with Kishon Investments, LLC ("Kishon") with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the "Kishon Commitment Fee Shares") of the Company's Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the "Kishon Note"), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company's common stock (the "Kishon Warrants"). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022, and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492.

During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. At December 31, 2023, principal and interest in the amount of $431,666 and $88,909, respectively, were due on the Kishon Note. At September 30, 2024, principal and interest in the amount of $431,666 and $147,238, respectively, were due on the Kishon Note. This note was in default at September 30, 2024.

Table of Contents

Finnegan Note 1

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the "Finnegan Note 1"). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1.

Principal and accrued interest in the amount of $51,765 and $11,889, respectively, were due on this note at December 31, 2023. At September 30, 2024, principal and interest in the amount of $51,765 and $18,372, respectively, were due on the Kishon Note. This note was in default at September 30, 2024.

Finnegan Note 2

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the "Finnegan Note 2"). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2.

At December 31, 2023principal and accrued interest in the amount of $32,353 and $7,341, respectively, were due on this note. At September 30, 2024, principal and interest in the amount of $32,353 and $11,352, respectively, were due on the Kishon Note. This note was in default at September 30, 2024.

Schrier Note

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the "Schrier Note"). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note.

At December 31, 2023, principal and accrued interest in the amount of $25,882 and $5,383, respectively, were due on this note. At September 30, 2024, principal and accrued interest in the amount of $25,882 and $8,578, respectively, were due on this note. This note was in default at September 30, 2024.

Table of Contents

Nommsen Note

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the "Nommsen Note"). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note.

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $13,685, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 22,565 shares of common stock. The Company recorded the shares at the closing price on the date of issuance, which resulted in a gain on the transaction of $80,282.

Caplan Note

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the "Caplan Note"). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note.

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $12,989, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 37,283 shares of common stock. The Company recorded the shares at the closing price on the date of issuance, which resulted in a gain on the transaction of $75,613.

Finnegan Note 3

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the "Finnegan Note 3") to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the "Finnegans"). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3.

Table of Contents

At December 31, 2023, principal and accrued interest in the amount of $32,353 and $6,350, respectively, were due on this note. At September 30, 2024, principal and accrued interest in the amount of $32,353 and $10,361, respectively, were due on this note. This note was in default at September 30, 2024.

Lightmas Note

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the "Lightmas Note"). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note.

At December 31, 2023, principal and accrued interest in the amount of $66,000 and $13,325, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 22,850 shares of common stock. The Company recorded the shares at the closing price on the date of issuance, which resulted in a gain on the transaction of $81,301.

Lewis Note

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the "Lewis Note"). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note.

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 12,409 shares of common stock. The Company recorded the shares at the closing price on the date of issuance, which resulted in a gain on the transaction of $40,385.

Goff Note

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the "Goff Note"). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note.

Table of Contents

Hagan Note

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the "Hagan Note"). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note.

At December 31, 2023, principal and accrued interest in the amount of $110,000 and $21,793, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 37,977 shares of common stock. The Company recorded the shares at the closing price on the date of issuance, which resulted in a gain on the transaction of $135,114.

Cavalry 2024 Note 1

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Cavalry Fund LLP ("Cavalry"), (the "Cavalry Note 1") with a due date of January 23, 2025. The Cavalry Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $25,000 and $1,843, respectively, were due on this note.

Cavalry 2024 Note 2

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Cavalry, (the "Cavalry Note 2") with a due date of February 28, 2025. The Cavalry Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $3,200, respectively, were due on this note.

Cavalry 2024 Note 3

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Cavalry, (the "Cavalry Note 3") with a due date of May 13, 2025. The Cavalry Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $33,000 and $1,266, respectively, were due on this note.

Cavalry 2024 Note 4

On July 19, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to Cavalry, (the "Cavalry Note 4") with a due date of July 19, 2025. The Cavalry Note 4 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

Table of Contents

At September 30, 2024, principal and accrued interest in the amount of $25,000 and $500, respectively, were due on this note.

Mercer 2024 Note 1

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Mercer Street Global Opportunity Fund ("Mercer"), (the "Mercer Note 1") with a due date of January 23, 2025. The Mercer Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $25,000 and $1,843, respectively, were due on this note.

Mercer 2024 Note 2

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mercer, (the "Mercer Note 2") with a due date of February 28, 2025. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $3,187, respectively, were due on this note.

Mercer 2024 Note 3

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Mercer, (the "Mercer Note 3") with a due date of May 13, 2025. The Mercer Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $33,000 and $1,248, respectively, were due on this note.

Mercer 2024 Note 4

On July 19, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to Mercer, (the "Mercer Note 4") with a due date of July 19, 2025. The Mercer Note 4 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $25,000 and $500, respectively, were due on this note.

Mercer 2024 Note 5

On September 6, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to Mercer, (the "Mercer Note 5") with a due date of September 6, 2025. The Mercer Note 5 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 5, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $25,000 and $164, respectively, were due on this note.

AJB 2024 Note 1

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB Capital Investments, LLC ("AJB"), (the "AJB Note 1") with a due date of February 28, 2025. The AJB Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $3,117, respectively, were due on this note.

Table of Contents

AJB 2024 Note 2

On May 15, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB, (the "AJB Note 2") with a due date of May 15, 2025. The AJB Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $1,248, respectively, were due on this note.

AJB 2024 Note 3

On July 19, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB, (the "AJB Note 3") with a due date of July 19, 2025. The AJB Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $500, respectively, were due on this note.

AJB 2024 Note 4

On September 6, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB, (the "AJB Note 4") with a due date of September 6, 2025. The AJB Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

At September 30, 2024, principal and accrued interest in the amount of $50,000 and $164, respectively, were due on this note.

Aggregate interest expense on the above notes payable was $140,643 for the nine months ended September 30, 2024. Accrued interest on notes payable was $214,681 and $348,821 at September 30, 2024, and December 31, 2023, respectively.

Note 9: Notes Payable - Related Parties

The following table summarizes the outstanding related party notes payable as of September 30, 2024, and December 31, 2023, respectively.

	September 30, 2024		December 31, 2023
M Diamond Note		64,706			64,706
Dobbertin Note		19,412			19,412
Lindstrom Note		45,294			45,294
Mitchell Note		-			78,100
Leath Note		-			55,000
November 29, 2022, Notes		37,500			37,500
Notes Payable		166,912			300,012

Current Portion, net of discount	$	166,912		$	300,012
Long-term portion, net of discount		-			-

Table of Contents

M Diamond Note

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the "M Diamond Note"). Ms. Diamond is the daughter of Larry Diamond, former CEO. The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note.

At December 31, 2023, principal and accrued interest in the amount of $64,706 and $14,682, respectively, were due on this note. At September 30, 2024, principal and accrued interest in the amount of $64,706 and $19,119, respectively, were due on this note. This note was in default at September 30, 2024.

Dobbertin Note

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the "Dobbertin Note"). Mr. Dobbertin is the spouse of Jenny Lindstrom, who was the Company's Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note.

At December 31, 2023, principal and accrued interest in the amount of $19,412 and $4,405, respectively, were due on this note. At September 30, 2024, principal and accrued interest in the amount of $19,412 and $6,790, respectively, were due on this note. This note was in default at September 30, 2024.

Lindstrom Note

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company's Chief Legal Officer (the "Lindstrom Note 1"). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1.

At December 31, 2023, principal and accrued interest in the amount of $45,294 and $10,277, respectively, were due on this note. At September 30, 2024, principal and accrued interest in the amount of $45,294 and $15,841, respectively, were due on this note. This note was in default at September 30, 2024.

Table of Contents

Mitchell Note

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the "Mitchell Note"). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note.

At December 31, 2023, principal and accrued interest in the amount of $78,100 and $15,768, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 27,040 shares of common stock. The amount was recorded as a contribution to capital as this is a related party note.

Leath Note

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the "Leath Note"). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $50,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note.

At December 31, 2023, principal and accrued interest in the amount of $55,000 and $10,757, respectively, were due on this note. During the nine months ended September 30, 2024, the Company entered into a settlement agreement with the lender to settle the note and all accrued interest in full in exchange for 18,052 shares of common stock. The amount was recorded as a contribution to capital as this is a related party note.

November 29, 2022, Notes

On November 29, 2022, the Company issued seven identical promissory notes (the "November 29 Notes") in related party transactions to the following individuals: (1) Thomas Brodmerkel, who was the Company's CFO and Board Member; (2) Lawrence Diamond, who was the Company's Chief Executive Officer and Board Member; (3) Sheila Schweitzer, who was a Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, who was a Board Member; (6) Jenny Lindstrom, who was the Company's former Vice President and Chief Legal Officer; and (7) Michael C. Howe, who was the Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the "November 29 Lenders").

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company's Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 13. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a "most favored nations" clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company's common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022, because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

Table of Contents

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the "November 29 Notes Exchange Agreements"). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

During the year ended December 31, 2023, interest in the amount of $11,967 was accrued on the November 29 Notes.

On September 29, 2023, three of the November 29 Lenders (1) Thomas Brodmerkel, (2) Lawrence Diamond, and (3) Faraz Naqvi converted their November 29 Notes into shares of the Company's Series F Preferred Stock as follows: Each of the noteholders converted an equity investment incentive in the amount of $13,553 representing 65% of the total amount due under the November 29 Note , along with original principal of $18,750 and accrued interest of $2,101 (a total of $34,404) into 34 shares of the Company's Series F Preferred Stock. Other than the equity investment incentives, there was no gain or loss recognized on this transaction as the Series F Preferred Stock was issued at its face value of $1,000 per share.

In each case at the time of the issuance of the Series F Preferred shares there were also certain notes, accrued fees, accrued salaries or other amounts included in the total renumeration before the conversion into the Series F Preferred shares.

On September 29, 2023, one of the November 29 Lenders, Sheila Schweitzer, converted her November 29 Note into shares of the Company's restricted common stock as follows: principal of $18,750 and accrued interest of $2,101 were converted at a price of $0.80 per share into 26,064 shares of the Company's common stock.

On December 8, 2023, pursuant to the Howe debt exchange agreement, Mr. Howe exchanged his note in the principal amount of $18,750 and accrued interest of $2,682 for certain assets of the company. No amounts were due under the Howe note as of December 31, 2023.

At December 31, 2023, there was principal and interest in the aggregate amount of $37,500 and $5,903, respectively, due on the two November 29 Notes that are still outstanding. At September 30, 2024, there was principal and interest in the aggregate amount of $37,500 and $8,731, respectively, due on the two November 29 Notes that are still outstanding.

Aggregate interest expense as described on the above notes payable - related parties was $31,639 for the nine months ended September 30, 2024. Accrued interest on notes payable - related parties were $50,481 and $61,792 at September 30, 2024, and December 31, 2023, respectively.

Note 10: Derivative Liabilities

Certain of the Company's convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management's judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

Derivative liability activity for the nine months ended September 30, 2024, is summarized in the table below:

December 31, 2023	$	152,945
True-up features issued		-
Settled upon conversion or exercise		-
Loss on revaluation		-
September 30, 2024	$	152,945

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations:

	September 30,			December 31,
	2024			2023
Volatility		475.7	%			475.7	%
Stock Price	$	0.0250			$	0.0250
Risk-free interest rates		5.21	%			5.21	%
Term (years)		0.39				0.39

Table of Contents

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

	●	The stock price would fluctuate with the Company projected volatility.
	●	The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.
	●	The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.
	●	In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.
	●	Discount rates were based on risk-free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

Note 11: Stockholders' Equity (Deficit)

Common Stock

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 8,508,756 were issued and outstanding at September 30, 2024.

During the nine months ended September 30, 2024, the Company issued 116,198 shares of common stock for dividends payable on its Series X Preferred Stock as discussed in further detail below. The price per share used in determining the number of shares issued was $.80, and not the lower price that is called for in the certificate of designation.

During the nine months ended September 30, 2024, the Company issued 300,000 shares of common stock in aggregate to its advisory board consisting of four (4) individuals, with 75,000 shares issued to each. The Company recorded a compensation expense of $102,500 based on the closing stock price on the date of issuance.

During the nine months ended September 30, 2024, the Company issued 300,000 shares of common stock in aggregate to its board of directors consisting of three (3) individuals, with 100,000 shares issued to each. The Company recorded a compensation expense of $75,000 based on the closing stock price on the date of issuance.

During the nine months ended September 30, 2024, the Company issued 231,886 shares of common stock for the settlement of outstanding payables with unrelated third parties. The Company valued the shares based on the closing stock price on the date of issuance and recorded a gain on settlement of $933,970.

During the nine months ended September 30, 2024, the Company issued 145,493 shares of common stock for the settlement of outstanding notes payables and accrued interest with unrelated third parties. The Company valued the shares based on the closing stock price on the date of issuance and recorded a gain on settlement of $453,079.

During the nine months ended September 30, 2024, the Company issued 45,092 shares of common stock for the settlement of outstanding notes payables and accrued interest with related parties. The Company recorded the settlement as contributions of capital and no gain or loss was recorded.

During the nine months ended September 30, 2024, the Company issued 1,602,130 shares of common stock for the conversion of Series D, Series F, and Series X preferred shares along with associated accrued dividends. The Company recorded the settlement as contributions of capital and no gain or loss was recorded.

Preferred Stock

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 31,427 shares as Series X Preferred Stock.

Table of Contents

Series A Preferred Stock

The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at September 30, 2024.

Series C Preferred Stock

The Series C Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series C ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder. The Company had no shares of Series C Preferred Stock outstanding at September 30, 2024.

Series D Preferred Stock

The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder. The Company had 150,000 shares of Series D Preferred Stock outstanding at September 30, 2024.

During the nine months ended September 30, 2024, a holder of 100,000 shares of Series D preferred shares along with $18,175 of accrued dividends agreed to convert the shares into 30,802 common shares at a conversion rate of $4 per common share. The Company recorded the settlement as contributions of capital and no gain or loss was recorded.

The Company accrued dividends in the amount of $11,738 on the Series D Preferred Stock for the nine months ended September 30, 2024. As of September 30, 2024, the Company had $27,362 in accrued dividends on the Series D Preferred Stock.

Series E Preferred Stock

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the "Series E") with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are no shares of Series E Preferred Stock outstanding at September 30, 2024. No shares of Series E Preferred Stock have ever been issued.

As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E.

Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon.

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the "Conversion Price"). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

Table of Contents

Series F Preferred Stock

On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock with the Delaware Secretary of State. The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has a liquidation preference of $1,000. The Series F Preferred Stock will rank senior to the Corporation's Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company.

Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock ("PIK Dividends") at rate of 12% per annum.

The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company's stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company's common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price.

There are 14,665 shares of Series F Preferred Stock outstanding at September 30, 2024.

On May 17, 2024, the holders of approximately 54.90% of the Series F Preferred shares, having met in person on May 8, 2024, have granted consent to the following modification to the terms of the Series F Preferred, effective May 15, 2024 all dividends, and any obligation to pay dividends shall cease. Any dividends accrued until May 15, 2024, shall be issued as noted in the original certificate of designation.

During the nine months ended September 30, 2024, holders of 5,392 shares of Series F preferred shares along with $630,502 of accrued dividends agreed to convert the shares into 1,515,065 common shares at a conversion rate of $4 per common share. The Company recorded the settlement as contributions of capital and no gain or loss was recorded.

The Company accrued dividends in the amount of $941,713 on the Series F Preferred Stock for the nine months ended September 30, 2024. As of September 30, 2024, the Company had $1,668,458 in accrued dividends on the Series F Preferred Stock.

Series X Preferred Stock

The Company has 24,587 and 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the "Series X Preferred Stock") outstanding as of September 30, 2024 and December 31, 2023. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company's common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company's common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in July 2023 the Company elected to use a price per share of $.80, a 20% discount to the average price of its common stock of $1.00, before the trading of its common stock was moved to the OTC Expert Market system. This policy has continued through September 30, 2024. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.

During the nine months ended September 30, 2024, the Company issued 7,200 shares of Series X Preferred Stock to the officers and directors of the compensation in lieu of services in the amount of $180,000 in aggregate, or $60,000 for each of the three (3) directors.

During the nine months ended September 30, 2024, the Company issued 116,198 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the second quarter of 2024 using the $.80 price per share as noted above.

During the nine months ended September 30, 2024, holders of 6,840 shares of Series X preferred shares agreed to convert the shares into 56,263 common shares at a conversion rate of $4 per common share. The Company recorded the settlement as contributions of capital and no gain or loss was recorded.

The Company accrued dividends in the amount of $58,926 on the Series X Preferred Stock for the nine months ended September 30, 2024. As of September 30, 2024, the Company had $0 in accrued dividends on the Series X Preferred Stock.

Table of Contents

Stock Options

On January 21, 2021, the Company filed a Form S-8 containing the Mitesco Omnibus Securities and Incentive Plan ("the Plan") with the SEC. In Sections 4.2 and 4.3 of the Plan it is noted that the Board of Directors has the authority for the administration of the Plan. On January 7, 2024, the Board of Directors voted to a) cancel, revoke and terminate any previously issued options that have not already been exercised. For a number of technical reasons, the Plan is no longer valid, and in addition to cancellation of any outstanding options, the Board has voted to formally terminate the Plan.

A copy of the Form S-8 which references the Plan can be found at: https://www.sec.gov/Archives/edgar/data/802257/000118518521000098/ex_221520.htm

The following table summarizes the options outstanding at September 30, 2024, and the related prices for the options to purchase shares of the Company's common stock:

Weighted

average

exercise

Range of

Number of

remaining

price of

Number of

price of

exercise

options

contractual

outstanding

options

exercisable

prices

outstanding

life (years)

options

exercisable

options

1.50

13,667

5.54

1.50

13,667

1.50

13,667

5.54

1.50

13,667

1.50

The following table summarizes the transactions involving options to purchase shares of the Company's common stock:

	Shares			Weighted- Average Exercise Price ($)
Outstanding at December 31, 2023		100,934			$	10.01
Granted		-				-
Cancelled/Expired		(87,267	)		$	11.38
Exercised		-				-
Outstanding at September 30, 2024		13,667			$	1.50
Options vested and exercisable		13,667			$	1.50

At September 30, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0. At September 30, 2024, there was no intrinsic value on the issued or vested options.

Warrants

The Company has announced that it intends to cancel all outstanding warrants, and certain language to complete this has been added to all documents related to the conversion of outstanding debts, notes, accounts payable and other senior securities. The following table summarizes the warrants outstanding on September 30, 2024, and the related prices for the warrants to purchase shares of the Company's common stock:

								Weighted					Weighted
					Weighted		average					average
					average		exercise					exercise
Range of		Number of		remaining		price of		Number of		price of
exercise		warrants		contractual		outstanding		warrants		exercisable
prices		outstanding		life (years)		warrants		exercisable		warrants
$	2.50		874			3.56		$	2.5		874			$	2.5
	25.00		184,916			1.86			25.00		283,616				25.00
	37.50		189,500			1.83			37.50		288,200				37.50
			375,290			1.85		$	31.26		572,690			$	31.26

Table of Contents

The following table summarizes the transactions involving options to purchase shares of the Company's common stock:

	Shares			Weighted- Average Exercise Price ($)

Outstanding at December 31, 2023		673,208			$	30.64
Granted		-			$	-
Cancelled		(100,518	)		$	(27.16	)
Exercised		-			$	-
Outstanding at September 30, 2024		572,690			$	31.26

At September 30, 2024, there was no intrinsic value on the issued or vested options.

Note 12: Fair Value of Financial Instruments

The following summarizes the Company's derivative financial liabilities that are recorded at fair value on a recurring basis at September 30, 2024, and December 31, 2023.

	September 30, 2024
	Level 1		Level 2			Level 3		Total
Liabilities
Derivative liabilities	$	-		$	-		$	152,945	$	152,945

	December 31, 2023
	Level 1		Level 2			Level 3		Total
Liabilities
Derivative liabilities	$	-		$	-		$	152,945	$	152,945

Note 13: Income Taxes

Deferred income taxes result from the temporary differences primarily attributable to amortization of intangible assets and debt discount and an accumulation of net operating loss carryforwards for income tax purposes with a valuation allowance against the carryforwards for book purposes.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Included in deferred tax assets are Federal and State net operating loss carryforwards of approximately $63.9 million and $14.1 million, respectively, which will expire through 2040. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Due to significant changes in the Company's ownership, the Company's future use of its existing net operating losses may be limited.

For the nine months ended September 30, 2024, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	2024

Expected tax at statutory rates	$	359,000		21	%
Permanent Differences		(3,000	)	0	%
State Income Tax, Net of Federal benefit		76,000		2	%
Other		36,000		4	%
Current Year Change in Valuation Allowance		(468,000	)	(27	)%
Prior Year True-Ups		-		0	%
Income tax expense	$	-		0	%

Table of Contents

Deferred income taxes reflect the tax impact of temporary differences between the amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations.

Deferred income taxes include the net tax effects of net operating loss (NOL) carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of September 30, 2024 and December 31, 2023 significant components of the Company's deferred tax assets are as follows:

	As of
	September 30, 2024			December 31, 2023
Deferred Tax Assets (Liabilities):
Accrued payroll	$	141,000			$	141,000
ASC842-ROU Asset		-				-
ASC842-ROU (Liability)		822,000				822,000
Loss from derivatives		(16,000	)			(16,000	)
Waiver and commitment fee shares		-				-
Stock based compensation		(244,000	)			(171,000	)
Depreciation		3,000				3,000
Net operating loss		13,133,000				13,529,000
Net deferred tax assets (liabilities)		13,839,000				14,308,000
Valuation allowance		(13,839,000	)			(14,308,000	)
Net deferred tax assets (liabilities)	$	-			$	-

Note 14: Commitments and Contingencies

Legal

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024, for total consideration consisting of a cash payment of $3,000.

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company's restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

The Company has a number of legal situations involved with the winding down of its clinic's business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

Nordhaus Clinic

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

Table of Contents

Egan Clinic a.k.a. Vikings

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023, and the Company has released the property back to the leaseholder.

St. Paul Clinic a.k.a. The Grove

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics' liens, and $64,600 in attorneys' fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

St. Louis Park Clinic a.k.a. Excelsior & Grand

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024, and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

Eden Prairie Clinic a.k.a. TP Elevate

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations for the amounts owed and is in the process of settling the remaining amounts owed.

Maple Grove Clinic a.k.a. Arbor Lakes

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

Radiant Clinic a.k.a. LMC Welton

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

Quincy Clinic a.k.a. 1776 Curtis

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

Table of Contents

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION	ALSO KNOWN AS:	PROPERTY NAME/OWNER	ORIGINAL OBLIGATION (NOT INC. CAPX)		SETTLEMENT AMOUNT		TYPE OF SETTLEMENT
MINNEAPOLIS, MN	NORDHAUS	LENNAR	$	511,000		$	-	N.A.
WAYZETTA, MN	PROMINADE	WAZETTA BAY	$	407,000		$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	EAGAN CLINIC	VIKINGS	$	767,000		$	488,491	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR & GRAND	EXCELSIOR	$	673,000		$	425,350	DEFAULT JUDGEMENT
ST. PAUL, MN	THE GROVE	CONTINENTAL 560	$	1,153,000		$	415,606	DEFAULT JUDGEMENT
EDEN PRARIE	ELEVATE	TP ELEVATE	$	620,000		$	-	IN PROCESS
MAPLE GROVE, MN	ARBOR LAKES	BUTTNICK	$	1,153,127		$	219,575	SETTLEMENT AGREE
DENVER, CO	LMC WELTON	RADIANT	$	782,000		$	530,000	DEFAULT JUDGEMENT
DENVER, CO	1776 CURTIS	QUINCY	$	1,079,000		$	348,764	DEFAULT JUDGEMENT
		TOTAL	$	7,145,127		$	2,452,768

Administrative offices

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not received any claims as to the obligations under this sublease agreement and the business from which we were renting has not responded to communications from our attorneys who have attempted to establish a formal settlement agreement since we have abandoned the location more than a year ago.

Note 15: Subsequent Events

Additional conversion of debt and senior securities

During the Q4 period of FY2024 the Company continued its restructuring efforts and has now completed the conversion of an additional $1,211,009 of its debts, notes and accounts payable into common stock at a price per share of $4.00 subsequent to September 30, 2024. These conversions resulted in the issuance of 260,095 shares of restricted common stock as of November 13, 2024. It is also in the process of eliminating its Series D and Series F Preferred shares held by certain of its accredited institutional investors through an exchange into a newly created Series A Amortizing Convertible Preferred stock. It expects to continue this effort through the remainder of the Q4 period of FY2024. Further details about the restructuring can be found in its Form 8k filing of October 24, 2024 at : https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518524001041/mitesco20241024_8k.htm.

Director Compensation

On November 13, 2024 the Board of Directors approved the issuance of 150,000 shares of restricted stock to each of the Directors for services provided through December 31, 2024, 450,000 shares in aggregate. Each of the two (2) disinterested Directors approved the issuances for the benefit of the other Director. The price per share at the time of the issuance was $.34 per share, and as such the charge to earnings for the issuance was $51,000 for each Director, or $153,000 in aggregate. This charge will be reflected in the Q4 period of FY2024.

Advisory Board Compensation

The Company appointed two (2) new members to its Advisory Board in October 2024. Each of the new members of the Advisory Board has been issued 75,000 shares of restricted common stock in consideration of their contributions for a 12-month term for an aggregate total shares of common stock of 150,000. The closing price per share at the time of the issuances was $0.55, resulting in a charge of $82,500, in aggregate This charge will be reflected in the Q4 period of FY2024.

Series X Preferred Stock Dividend Issuance

The Company issued 4,417 shares of restricted common stock in consideration of dividend payments for October 2024. The closing price per share as of the 15^th of October, the prescribed date for the payment of Series X Preferred stock dividends was $.57 per share. Each of the Directors holds a certain number of Series X Preferred shares as noted below. Further, as of November 16, 2024 it has issued a total of 7,463 shares of restricted common stock in consideration of the payment of the Series X dividends for the November 2024 period based on a closing price of $.55 on November 15, 2024.

Table of Contents

Change in voting control

Subsequent to September 30, 2024, two additional holders of the Company's Series X Preferred stock have opted to exchange 4,884 shares for 30,525 shares common stock in the restructuring note above. As a result, the number of Series X Preferred stockholders has been reduced to four (4), as shown in the table below. The shares were exchanged based on the face value of $25 per share, and the price per share for the common stock issued in the exchange was $4.00.

NAME	NUMBER OF SERIES X PREFERRED SHARES	VOTES AT 400 EACH	ADD COMMON SHARES OWNED	TOTAL VOTING	% OF TOTAL SHARE VOTES
MACK LEATH	2,400	960,000	275,873	1,235,873	7.16%
JORDAN BALENCIC	2,400	960,000	256,534	1,216,534	7.05%
JOHN MITCHELL	2,400	960,000	297,913	1,257,913	7.29%
ANGLO IRISH MANAGEMENT LLC	12,503	5,001,200	157,795	5,158,995	29.88%
Total	19,703	7,881,200		7,881,200	45.65%

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the "Company," "Mitesco, Inc.," "our," "us" or "we" refer to Mitesco, Inc. The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

History and Outlook

We are a holding company seeking to provide products, services and technology. From 2020 through 2022, the Company was executing against a strategic plan to open primary care clinics utilizing advanced degreed nurse practitioners in select markets. The clinics operated under the name The Good Clinic. However, the business failed to achieve profitability, and the markets were not favorable to additional funding, therefore in late 2022 the decision was made to close the clinics and release all employees.

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as "managed services offerings" or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. The second focus involves hosting application software developed by software vendors, from which they will sell the use of the software by their end user clients on a "cloud" basis. By taking this approach, we gain the business of the vendor, and their clients, perhaps allowing us to grow at a faster rate with lower cost of sales. We have developed the "Centcore Partner Program" where we will help promote the software vendors who are hosting in our data centers. If we are successful helping the vendor grow his business, we will have provided a "value added service", and benefit from increased utilization of our computing resources by not only the vendor, but also his new end user clients. Our initial focus for this area is on software providers who serve the "infrastructure" market doing design, engineering, construction and maintenance of significant assets. We desire to create "life cycle" relationships with both the design teams, and owners which may include private owners such as manufacturers and utilities, or publicly owned assets for municipalities, states or federal governments, domestically and internationally.

We have retained proven professionals in the data center, cyber security and infrastructure services areas to support our needs on a per hour basis, which we believe will allow us to control our costs relative to business activity, without significant staffing internally. The Vero Technology Ventures arm is actively reviewing potential early-stage cloud computing solution vendors and is developing its own artificial intelligence (A.I.) based application set. The new 'Robo' application utilizes A.I. to promote more efficient sales and marketing within certain markets, and with highly targeted market research.

Table of Contents

Advisory Board Expansion

The current board comprises individuals with specific expertise to assist Mitesco in finding and evaluating qualified companies and businesses for integration into the public holding company. The Advisory Board is a non-executive board, and its participants shall not be subject to any of the regulations under Section 16 of the Securities Act. Each member of the Advisory Board has been issued 75,000 shares of restricted common stock in consideration of their contributions for a 12-month term.

The latest appointments to the Advisory Board are executives whose careers have focused on data center business development and data center systems software, as noted here:

Gabriel Crawford has over 20 years' experience in data center development from site selection, design/ build/ engineering services, and, most recently, hyperscale and AI co-location leasing.

Most recently, Mr. Crawford was at Dallas-based Center Square DC, which specializes in delivering a comprehensive suite of colocation and data center services with more than 50 data centers owned and operated. Prior to that engagement, he was with Chirisa Investments creating long-term value for customers in digital infrastructure, communications and real estate. While at Digital Fortress, a privately-held data center co-location company based in Seattle, Washington, he managed more than 1,500 clients who entrusted their applications and servers to their mission-critical facilities and network with data centers in Seattle, WA, Tukwila, WA, Lynwood, WA, Denver, CO and Chicago, IL. Earlier in his career, Mr. Crawford held positions at both early stage and mature data center operators, in addition to offering consulting services. His educational background includes a bachelor's degree from the University of Maine. He is based in Vero Beach, Florida.

Jim Clifton is a senior sales and marketing executive focused on systems software, data analytics and innovative implementation to improve productivity across corporations and workforces worldwide.

Most recently, Mr. Clifton drove sales at Alteryx, an intuitive, code-free platform for data preparation, blending, analytics, and automation. Prior to that he was with VMware, developing both cloud and on-prem business to expand the utilization of systems across disparate users. While at Cumberland Group he headed a practice aimed at IoT productivity using real-time dashboards and other online tools. At Star Mobile he focused on mobile application implementation of corporate cloud-based applications. Other professional sales and management positions included Citrix, Symantec and Verisign, where he oversaw implementation of new technologies for key corporate clients. Jim's education includes a bachelor's degree from the University of Georgia and a master's degree from Mercer University. He is based in St. Simons, Georgia

Results of Operations

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period of any future periods. Results of discontinued operations are excluded from the accompanying results of operations for all periods presented, unless otherwise noted. See Note 3 - discontinued operations in the accompanying notes to consolidated financial statements. Further, as a result of any acquisitions of other businesses, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

Comparison of the Three Months Ended September 30, 2024, and 2023.

Revenues

We had revenues of $23,500 for the three months ended September 30, 2024, compared to $0 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC.

Operating Expenses

Our total operating expenses for the three months ended September 30, 2024, were $239,742. For the comparable period in 2023, the operating expenses were $41,876. The increase is the result of the Company's focus on establishing the operations of its newly formed subsidiaries.

Other Income and Expenses

Interest expense was $50,979 for the three months ended September 30, 2024, compared to $69,776 for the three months ended September 30, 2023. The decrease was a result of reduced debt balances in the current period.

Interest expense - related parties was $10,587 for the three months ended September 30, 2024, compared to $34,820 in the prior period. The decrease was a result of reduced debt balances in the current period.

Table of Contents

During the three months ended September 30, 2023, we recorded equity investment incentives of approximately $1.2 million. There were no comparable transactions in the current period.

During the three months ended September 30, 2024, we recorded a gain on settlement of debt of $693,768 compared to $25,000 for the three months ended September 30, 2023.

During the three months ended September 30, 2024, we recorded a gain on settlement of accounts payable of $1,024,583 compared to $159,524 for the three months ended September 30, 2023.

During the three months ended September 30, 2023, we recorded a loss on revaluation of derivative liabilities of $14,725. There were no comparable transactions in the current period.

For the three months ended September 30, 2024, we had a net loss available to common shareholders from discontinued operations of $0, compared to a net loss available to common shareholders from discontinued operations of $376,352 for the three months ended September 30, 2023.

Comparison of the Nine Months Ended September 30, 2024, and 2023.

Revenues

We had revenues of $29,500 for the nine months ended September 30, 2024, compared to $0 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC.

Operating Expenses

Our total operating expenses for the nine months ended September 30, 2024, were $721,095. For the comparable period in 2023, the operating expenses were $2,362,056. The decrease is the result of the winding down of the Company's clinic operations with The Good Clinic, LLC subsidiary.

Other Income and Expenses

Interest expense was $159,206 for the nine months ended September 30, 2024, compared to 1,575,278 for the nine months ended September 30, 2023. The decrease was a result of reduced debt balances in the current period.

Interest expense - related parties was $26,133 for the nine months ended September 30, 2024, compared to $108,343 in the prior period. The decrease was a result of reduced debt balances in the current period.

During the nine months ended September 30, 2024, we recorded a gain on termination of operating lease of $869,690. There were no comparable transactions in the prior period.

During the nine months ended September 30, 2023, we recorded equity investment incentives of approximately $7.6 million. There were no comparable transactions in the current period.

During the nine months ended September 30, 2024, we recorded a gain on settlement of debt of $693,768 compared to $25,000 for the nine months ended September 30, 2023.

During the nine months ended September 30, 2023, we recorded a gain on sales of assets of $20,097. There were no comparable transactions in the current period.

During the nine months ended September 30, 2024, we recorded a gain on settlement of accounts payable of $1,024,583 compared to $33,092 for the nine months ended September 30, 2023.

During the nine months ended September 30, 2023, we recorded a loss on settlement of true-up obligation of $119,370. There were no comparable transactions in the current period.

During the nine months ended September 30, 2023, we recorded a loss on legal settlement of $18,759. There were no comparable transactions in the current period.

Table of Contents

During the nine months ended September 30, 2023, we recorded a loss on revaluation of derivative liabilities of $85,765. There were no comparable transactions in the current period.

For the nine months ended September 30, 2024, we had a net loss available to common shareholders from discontinued operations of $0, compared to a net loss available to common shareholders from discontinued operations of $3,075,155.

Liquidity and Capital Resources

To date, we have not generated sufficient revenue from operations to support our operations. We have financed our operations through the sale of equity securities and short-term borrowings. As of November 21, 2024, we had cash of approximately $114,000 compared to cash of approximately $32,000 as of September 30, 2024. Our Company's recurring losses from operations and negative cash flows from operations and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern.

Net cash used in operating activities was $399,775 for the nine months ended September 30, 2024. This is the result of the winding down of the Company's clinic operations. Cash used in operations for the nine months ended September 30, 2023, was $845,947, of which $428,688 was related to cash used in operating activities from discontinued operations.

The Company had no investing activities for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company received cash of $102,967 related to the sale of fixed assets used in discontinued operations.

Net cash provided by financing activities for the nine months ended September 30, 2024, was $428,759, compared to $733,664 for the nine months ended September 30, 2023. Cash provided by financing activities was the result of cash proceeds from notes payable of $449,000, offset by the repayment of principal on the SBA loan in the amount of $20,241.

At September 30, 2024, we had the following current liabilities which are payable in cash: Accounts payable and accrued liabilities of $5.7 million; notes payable of $1.0 million; notes payable to related parties of $0.2 million; SBA Loan Payable of $0.4 million; legal settlements of $2.5 million; accrued interest payable of $0.4 million; accrued interest payable to related parties of $0.01 million; and other current liabilities of $0.1 million. We also have the following liabilities which are payable in stock: derivative liabilities of $0.2 million, preferred stock dividends of $1.7 million, and preferred stock dividends payable to related parties of $0.2 million.

We have agreements from three (3) of our institutional investors to provide interim funding so that the Company may stay current with its accounting and reporting requirements under the Securities Act of 1934, settle obligations from the prior healthcare clinic operations and find a new business area to engage within. Through September 30, 2024, the total amount loaned under 12-month, 10% interest simple notes are $449,000, with roughly $250,000 attributable to accounting and compliance, $50,000 generally related to settlements and legal related, with the remaining for general expenses including T&E and communications.

In May 2024 we reached an agreement with the holders of our Series F Preferred shares to wave all interest payments permanently beginning May 15, 2024. This creates a reduction in accrued interest of over $200,000 per month. Similar adjustments with other holders of debt and interest paying equity are expected.

The Company is working with its institutional investors on a plan to eliminate all existing obligations through the issuance of a new preferred stock which would be issued to the holder in lieu of debt. It is envisioned that this stock would be listed and traded separately from the Company's common stock. This plan is in its early stages and there can be no guarantee that it will be fully implemented, approved by the SEC for trading, or accepted by all creditors, some of which may be required to see a reduction in the amounts currently owned in order to get consent from the larger investor group.

The Company has relationships with a number of consultants who are assisting in the creation of the new business units. It is anticipated that this approach will continue indefinitely as it does not desire to create the overhead associated with a large employment force.

Table of Contents

The following table summarizes the status of our property-related settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION	ALSO KNOWN AS:	PROPERTY NAME/OWNER	ORIGINAL OBLIGATION (NOT INC. CAPX)		SETTLEMENT AMOUNT		TYPE OF SETTLEMENT
MINNEAPOLIS, MN	NORDHAUS	LENNAR	$	511,000		$	-	N.A.
WAYZETTA, MN	PROMINADE	WAZETTA BAY	$	407,000		$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	EAGAN CLINIC	VIKINGS	$	767,000		$	488,491	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR & GRAND	EXCELSIOR	$	673,000		$	425,350	DEFAULT JUDGEMENT
ST. PAUL, MN	THE GROVE	CONTINENTAL 560	$	1,153,000		$	415,606	DEFAULT JUDGEMENT
EDEN PRARIE	ELEVATE	TP ELEVATE	$	620,000		$	-	IN PROCESS
MAPLE GROVE, MN	ARBOR LAKES	BUTTNICK	$	1,153,127		$	219,575	SETTLEMENT AGREE
DENVER, CO	LMC WELTON	RADIANT	$	782,000		$	530,000	DEFAULT JUDGEMENT
DENVER, CO	1776 CURTIS	QUINCY	$	1,079,000		$	348,764	DEFAULT JUDGEMENT
		TOTAL	$	7,145,127		$	2,452,786

Critical Accounting Estimates

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

●

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such an evaluation, the Company's management has identified what it believes are material weaknesses in the Company's disclosure controls and procedures and concluded that we did not have effective disclosure controls and procedures.

The deficiencies in our disclosure controls and procedures included (i) lack of segregation of duties and (ii) lack of sufficient resources to ensure that information required to be disclosed by the Company in the reports that the Company files or submits to the SEC are recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules and forms.

The Company intends to take corrective action to ensure that information required to be disclosed by the Company pursuant to the reports that the Company files or submits to the SEC is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the nine months ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company's restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

Nordhaus Clinic

Egan Clinic a.k.a. Vikings

St. Paul Clinic a.k.a. The Grove

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics' liens, and $64,600 in attorneys' fees. The final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

St. Louis Park Clinic a.k.a. Excelsior & Grand

Eden Prairie Clinic a.k.a. TP Elevate

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations with the amounts owed and is in the process of settling the remaining amounts owed.

Table of Contents

Maple Grove Clinic a.k.a. Arbor Lakes

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

Radiant Clinic a.k.a. LMC Welton

Quincy Clinic a.k.a. 1776 Curtis

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

The following table summarizes the status of our property-related settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION	ALSO KNOWN AS:	PROPERTY NAME/OWNER	ORIGINAL OBLIGATION (NOT INC. CAPX)		SETTLEMENT AMOUNT		TYPE OF SETTLEMENT
MINNEAPOLIS, MN	NORDHAUS	LENNAR	$	511,000		$	-	N.A.
WAYZETTA, MN	PROMINADE	WAZETTA BAY	$	407,000		$	25,000	CASH PAYMENT OBLIGATION
EAGAN, MN	EAGAN CLINIC	VIKINGS	$	767,000		$	488,491	DEFAULT JUDGEMENT
ST. LOUIS PARK, MN	EXCELSIOR & GRAND	EXCELSIOR	$	673,000		$	425,350	DEFAULT JUDGEMENT
ST. PAUL, MN	THE GROVE	CONTINENTAL 560	$	1,153,000		$	415,606	DEFAULT JUDGEMENT
EDEN PRARIE	ELEVATE	TP ELEVATE	$	620,000		$	-	IN PROCESS
MAPLE GROVE, MN	ARBOR LAKES	BUTTNICK	$	1,153,127		$	219,575	SETTLEMENT AGREE
DENVER, CO	LMC WELTON	RADIANT	$	782,000		$	530,000	DEFAULT JUDGEMENT
DENVER, CO	1776 CURTIS	QUINCY	$	1,079,000		$	348,764	DEFAULT JUDGEMENT
		TOTAL	$	7,145,127		$	2,452,768

Administrative offices

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not entered into a settlement agreement on this site as of the date of this filing but expect to shortly.

ITEM 1A. RISK FACTORS

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 16, 2024. There have been no material changes to the risk factors described in that report.

Table of Contents

ITEM 2. SALE OF UNREGISTERED SECURITIES

Common Stock

On September 19, 2024, the Company issued a total of 25,573 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the third quarter of 2024 using the $.80 price per share as noted above.

During the three months ended September 30, 2024, the Company issued 300,000 shares of common stock to its board of directors. The Company recorded a compensation expense of $72,000 based on the closing stock price on the date of issuance.

During the three months ended September 30, 2024, the Company issued 200,000 shares of common stock to consultants. The Company recorded a compensation expense of $29,250 based on the closing stock price on the date of issuance.

ITEM 3. DEFAULTS ON SENIOR SECURED SECURITIES

Not Applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

Not Applicable.

ITEM 6. EXHIBITS

The following exhibits are included with this Quarterly Report on Form 10-Q.

		Form Type	Exhibit Number	Date Filed	Filed Herewith

3.1	Certificate of Incorporation of Trunity Holdings, Inc., dated January 18, 2012.	8-K	10.1	1/31/2012

3.2	Bylaws of Trunity Holdings, Inc., dated January 18, 2012.	8-K	10.2	1/31/2012

3.3	Certificate of Ownership Merging between Trunity Holdings, Inc. and Brain Tree International, Inc. dated January 24, 2012.	10-K	3.3	4/16/2013

3.4	Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated December 24, 2015.	8-K	3.1(i)	1/06/2016

3.5	Certificate of Designations of Series X Preferred Stock of True Nature Holding, Inc.	8-K	3.6	1/06/2020

3.6	Form of Amended and Restated Certificate of Designations of Series A Preferred Stock of True Nature Holding, Inc.	8-K	3.07	3/13/2020

3.7	Certificate of Amendment of the Certificate of Incorporation of True Nature Holding, Inc. dated April 21, 2020.	10-Q	3.7	8/14/2020

3.8	Certificate of Amendment of Certificate of Incorporation, dated as of November 5, 2020, correcting December 24, 2015, Certificate of Amendment.	10-Q	3.8	11/13/2020

Table of Contents

		Form Type	Exhibit Number	Date Filed	Filed Herewith

3.9	Bylaws of Mitesco, Inc., as amended, dated November 10, 2020	10-Q	3.9	11/13/2020

3.10	Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.	8-K	3.1	03/26/2021

3.11	Certificate of Correction to the Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.	8-K	3.2	03/26/2021

31.1	Certification by the Principal Executive Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X

32.1	Certification by the Principal Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X

101.INS **	XBRL INSTANCE DOCUMENT

101.SCH **	XBRL TAXONOMY EXTENSION SCHEMA

101.CAL **	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

101.DEF **	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

101.LAB **	XBRL TAXONOMY EXTENSION LABEL LINKBASE

101.PRE **	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

#	Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.

Table of Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q for the period ended September 30, 2024, to be signed on its behalf by the undersigned, thereunto duly authorized.


	MITESCO, INC.

Dated: November 25, 2024	By:	/s/ Mack Leath
		Mack Leath Chief Executive Officer, Chief Financial Officer and Principal Financial Officer

Sharing and Personal Tools

Please select the service you want to use:

Back

View original format